论文部分内容阅读
目的探讨上海市南汇区恶性肿瘤患者生存率状况,为恶性肿瘤社区防治提供依据。方法对南汇区2002—2004年恶性肿瘤登记报告系统中新发肿瘤病例5783例进行随访,获得生存资料,随访病例用SPSS软件的寿命表和Kaplan-Meier生存曲线法计算生存率,Log-rank检验法比较组间生存率。结果该区2002—2004年居民恶性肿瘤发病率为267.57/10万,标化率为209.98/10万,发病前5位依次为肺癌、肝癌、胃癌、肠癌和食管癌,标化发病率依次为43.06/10万,28.65/10万,26.82/10万,18.63/10万和9.57/10万。女性生存率(36.49%)高于男性(22.19%),差别有统计学意义(χ2=137.4,P<0.005),前5位恶性肿瘤1a生存率从低到高,男性依次为肝癌(12.15%)、肺癌(15.47%)、食管癌(17.17%)、胃癌(37.55%)和肠癌(58.68%),女性依次为肝癌(10.45%)、食管癌(13.85%)、肺癌(15.13%)、胃癌(31.94%)和肠癌(56.49%)。女性乳腺癌5a生存率为78.20%。男女性恶性肿瘤的生存率随年龄上升而下降(P<0.05)。结论南汇区恶性肿瘤患者中肠癌和女性乳腺癌的生存情况较好,肝癌、肺癌和食管癌的生存情况较差。
Objective To investigate the survival rate of patients with malignant tumor in Nanhui District, Shanghai, and to provide basis for community prevention and treatment of malignant tumor. Methods 5783 newly diagnosed tumor cases from 2002 to 2004 in Nanhui District were followed up to obtain survival data. Survival rates were calculated by SPSS software SPSS software and Kaplan-Meier survival curve. Log-rank test Law compared the survival rate between groups. Results The incidence of malignant tumors among residents was 267.57 / 100 000 in 2002-2004, with the standardization rate of 209.98 / 100 000. The top five diseases were lung cancer, liver cancer, gastric cancer, intestinal cancer and esophageal cancer, 43.06 / 100,000, 28.65 / 100,000, 26.82 / 100,000, 18.63 / 100,000 and 9.57 / 100,000. The survival rate of women in the first five malignant tumors was from low to high, followed by liver cancer (12.15% , Lung cancer (15.47%), esophageal cancer (17.17%), gastric cancer (37.55%) and colorectal cancer (58.68%). Female patients in turn were liver cancer (10.45%), esophageal cancer (13.85% Gastric cancer (31.94%) and colorectal cancer (56.49%). The survival rate of female breast cancer 5a was 78.20%. The survival rate of male and female malignant tumors decreased with age (P <0.05). Conclusion The survival of patients with malignant tumors in the Nanhui District is better than that of the patients with cancer of the colon and the cancers of the female. The survival of liver cancer, lung cancer and esophageal cancer is poor.